| pubmed-article:16652052 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C0205466 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C0026882 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C0035379 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C2698872 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C0017431 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C0085862 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C1299583 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C0231174 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C0085405 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C1608386 | lld:lifeskim |
| pubmed-article:16652052 | lifeskim:mentions | umls-concept:C1549571 | lld:lifeskim |
| pubmed-article:16652052 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16652052 | pubmed:dateCreated | 2006-5-2 | lld:pubmed |
| pubmed-article:16652052 | pubmed:abstractText | Patients infected with HIV-1 with more than 1000 HIV-1 RNA copies/mL, who were genotyped within 3 months before starting stavudine and treated for at least 3 months with a stable stavudine-containing highly active antiretroviral therapy, were selected from our database to identify the determinants of response to stavudine. Nonresponse was defined as a failure to achieve HIV-1 RNA level of less than 400 copies/mL or a reduction of more than 2 log10 by week 12. Univariate logistic analysis was used to elicit the failure-associated reverse transcriptase mutations (scored 1 to develop a genotype score). Eighty-one patients were eligible for the analysis, including 75 (93%) who previously received zidovudine. Thirty-five (43%) were nonresponders. Univariate logistic analysis revealed the following failure-associated mutations: 41L (P = 0.0001), 44D (P = 0.02), 118I (P = 0.0006), 184V (P = 0.04), 210W (P = 0.0004), and 215Y (P = 0.002) for a median stavudine score of 2. Failure was observed in 7 (18.9%) of 37 patients with a score less than 2, compared with 28 (63.6%) of 44 patients with a score of 2 or greater (P < 0.0001). The multivariable analysis showed that the 118I mutation (P = 0.04) was the only independent genotypic predictor of failing on a stavudine- containing highly active antiretroviral therapy. | lld:pubmed |
| pubmed-article:16652052 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16652052 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652052 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16652052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652052 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16652052 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16652052 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:16652052 | pubmed:issn | 1525-4135 | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:LazzarinAdria... | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:GalliLauraL | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:GianottiNicol... | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:De BonaAnnaA | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:BoeriEnzoE | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:CastagnaAnton... | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:GuffantiMonic... | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:DaniseAnnaA | lld:pubmed |
| pubmed-article:16652052 | pubmed:author | pubmed-author:SalpietroStef... | lld:pubmed |
| pubmed-article:16652052 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16652052 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16652052 | pubmed:volume | 41 | lld:pubmed |
| pubmed-article:16652052 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16652052 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16652052 | pubmed:pagination | 447-52 | lld:pubmed |
| pubmed-article:16652052 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:meshHeading | pubmed-meshheading:16652052... | lld:pubmed |
| pubmed-article:16652052 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16652052 | pubmed:articleTitle | The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients. | lld:pubmed |
| pubmed-article:16652052 | pubmed:affiliation | Clinic of Infectious Diseases, Vita-Salute San Raffaele University, Italy. gianotti@hsr.it | lld:pubmed |
| pubmed-article:16652052 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16652052 | lld:pubmed |
